Join to View Full Profile
460 West 12th AvenueColumbus, OH 43210
Dr. Memmott is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2018 - 2020
University of Arizona College of Medicine-PhoenixChief Residency, Internal Medicine, 2017 - 2018- University of Arizona College of Medicine-PhoenixResidency, Internal Medicine, 2014 - 2017
University of Cincinnati College of MedicineClass of 2012
Certifications & Licensure
OH State Medical License 2018 - 2026
AZ State Medical License 2017 - 2020
FL State Medical License 2017 - 2019
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
AOA Board of Internal Medicine Oncology
Clinical Trials
- Osimertinib and Tegavivint As First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer Start of enrollment: 2022 Jan 18
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients.Anet Greib, Songzhu Zhao, Michelle Ploch, Jonathan Henricks, Robert Easterling
Oncoimmunology. 2025-12-01 - CLO25-080: Outcomes of Extreme Low PD-L1 Expression in Advanced Non-Small Cell Lung Cancer: Implications for Treatment Approaches.Alexander Rudich, Natalie Johns, Songzhu Zhao, Kenneth Chian, Po-Lan Su
Journal of the National Comprehensive Cancer Network. 2025-03-28 - CLO25-053: Real-World Evidence of Survival in Patients With Metastatic NSCLC Treated With First-Line Immune Checkpoint Inhibitors Beyond Progression.Natalie Johns, Alexander Rudich, Songzhu Zhao, Kenneth Chian, Po-Lan Su
Journal of the National Comprehensive Cancer Network. 2025-03-28
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
